Abstract
Four randomized placebo-controlled efficacy trials of a candidate vaccine or passively infused monoclonal antibody for prevention of HIV-1 infection are underway (HVTN 702 in South African men and women; HVTN 705 in sub-Saharan African women; HVTN 703/HPTN 081 in sub-Saharan African women; HVTN 704/HPTN 085 in U.S., Peruvian, Brazilian, and Swiss men or transgender persons who have sex with men). Several challenges are posed to the optimal design of the sequel efficacy trials, including: (1) how to account for the evolving mosaic of effective prevention interventions that may be part of the trial design or standard of prevention; (2) how to define viable and optimal sequel trial designs depending on the primary efficacy results and secondary "correlates of protection" results of each of the ongoing trials; and (3) how to define the primary objective of sequel efficacy trials if HIV-1 incidence is expected to be very low in all study arms such that a standard trial design has a steep opportunity cost.
Introduction: The Success Paradox in HIV Prevention
We are currently in a "golden age" of HIV prevention research, with several large-scale trials for vaccines and broadly neutralizing antibodies (bNAbs) underway. However, these trials face a looming "success paradox." As existing interventions like daily oral Pre-Exposure Prophylaxis (PrEP) and medical circumcision become the "standard of prevention," background HIV incidence rates successfully decline.
While this is a public health victory, it complicates the design of future "sequel" trials. It becomes ethically difficult to use a pure placebo group in future trials. Furthermore, as these tools successfully lower the number of new infections, the sample sizes required to statistically prove that a new intervention is even better become prohibitively large and expensive. This paper outlines a framework for designing scientifically rigorous and logistically feasible sequel trials.
Current Landmark Efficacy Trials
Two primary vaccine efficacy trials currently provide the foundation for future research: HVTN 702 and HVTN 705. These studies are testing different biological approaches to eliciting immunity.
HVTN 702: The South African Vaccine Trial
HVTN 702 is a large-scale study in South Africa testing a pox-protein prime-boost regimen. It aims to build upon the modest success of the RV144 trial in Thailand, adapted for the Clade C virus prevalent in the region.
HVTN 705: The Mosaic Vaccine Trial
HVTN 705, also known as the Imbokodo study, is testing a "mosaic" vaccine designed to provide broad protection against various HIV strains globally. This trial focuses on women in several sub-Saharan African countries.
Methodological Framework for Sequel Trials
To address the challenges of declining incidence and evolving standards of care, three primary randomized trial designs are proposed for studying a new intervention (A) while accommodating a proven intervention (B):
- Layer Design: Facilitated access to B is provided to all participants. The trial compares A vs. a placebo for A. This is efficient but assumes A and B are distinct enough in modality (e.g., a vaccine vs. a daily pill).
- Compare Design: Participants are randomized to receive either A or B. This often leads to non-inferiority trials, which require proving that A is "not much worse" than B. This can increase required sample sizes by 4 to 5 times compared to layer designs.
- Combine Design: Compares A + B vs. B alone. This is ideal for testing if a new vaccine adds a meaningful "layer" of protection on top of existing PrEP.
Statistical Science and Correlates of Protection
The most critical factor for sequel design is identifying a "correlate of protection" (CoP). If the first trial proves that a specific host immunological marker predicts immunity, the sequel trial might only need to prove the new intervention reaches that level (immuno-bridging), rather than waiting years for infections to occur.
Furthermore, the paper discusses counterfactual placebo analysis, which uses statistical modeling to estimate what the infection rate would have been without any intervention. While this approach is fraught with risks for bias due to unverifiable assumptions, it may become a necessary tool when traditional placebo arms are no longer feasible. Reliability would require new techniques, such as using other STIs as validated exposure markers or establishing permanent sentinel surveillance cohorts.
Conclusion
The transition from current efficacy trials to their sequels requires a shift in statistical thinking. By leveraging correlates of protection, exploring novel randomized designs, and refining counterfactual modeling, the research community can continue to innovate even as the landscape of HIV prevention successfully evolves.
Summary updated